alexa All High Risk? Pathologic Extracapsular Extension In The Era Of Human Papillomavirus Associated Head/ Neck Cancers
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Global Annual Oncologists Meeting
April 24-25, 2017 Dubai, UAE

Tarek Dufan, Anthony N Snow, Sarah L Mott, Michael Laszweski, Andrew Hetland, Andrew Terrell, Bill Liu, Catherine Fisher, Carryn M Anderson, J Kyle Russo and John M Watkins
American Hospital Dubai, UAE
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-096
Purpose/Objective(s): Extracapsular extension (ECE) is an established risk factor for head/neck cancer (HNCa) recurrence and mortality; however, it is unknown if nodal ECE remains a negative prognostic factor in Human Papillomavirus (HPV)+ HNCa. Materials & Methods: Retrospective multi-institutional comparative outcomes analysis of patient- and tumor-specific factors was done by HPV association. Eligible patients had pathologic confirmation of ECE for squamous cell carcinoma of the HN involving the oropharynx (OP), oral cavity (OC), or unknown primary (UP), and underwent curative-intent therapy. Patients with metastatic disease at diagnosis, unknown HPV/p16 status, or <3 month follow-up were excluded. Results: Between the period from 2003 to 2014, 76 patients were found eligible for the present analysis. The median age at diagnosis was 60 years (range 29-82), with 46 OP cases, 28 OC, and 2 UP. Forty-one patients had HPV+ tumors.All but 5 patients had therapeutic neck dissection, and the primary site was resected in 65 patients. For resected primary cases, 38, 23, and 4 patients underwent adjuvant chemoradiotherapy (CRT), radiotherapy (RT) alone, and no adjuvant therapy, respectively. For 9 patients who underwent definitive RT, 7 received concurrent CRT. Of note, 40% of HPV+ and 35% of HPV– patients did not receive chemotherapy (p=NS). The median number of nodes excised and involved were 27 (1-92) and 2 (1-32), respectively. At a median follow-up of 26.3 months (1.4-104.0; median 34.1 for survivors), 52 patients were alive (48 without recurrence, 4 with salvaged recurrence) and 24 patients had died (21 of HNCa).Patterns of failure included local (n=6), regional (6), locoregional + distant (6), and distant only (4). In comparing the HPV+ and HPV– groups, disease-free and overall survival was superior for the HPV+ group (p<0.01; Table). HPV+ cases were more likely to be male (93% vs. 51%), undergo definitive RT (30% vs. 20%), have higher stage (73% vs. 49% stage IV) and larger nodal size (median 3.6 vs. 1.9 cm), and less likely to have undergone resection of primary (78% vs. 94%). There were no differences in number of lymph nodes sampled or involved or in follow-up between the groups. Conclusion: HPV+ HNCa with ECE has an excellent prognosis despite the propensity for advanced AJCC stage and large pathologic nodal size. This excellent prognosis persists without the use of chemotherapy. Prognosis in the HPV– population with ECE remains poor despite therapeutic escalation using modern multimodality therapy (surgery, chemotherapy and radiation). ECE in the HPV+ population should be re-evaluated as a negative prognostic factor and indicator for therapeutic escalation.

Tarek Dufan is currently serving as a Medical Director of Bismarck Cancer Center. He is also a Cancer Committee Chair, CHI St. Alexius Health Center, Bismarck, ND and also acting as an Associate Professor at University of North Dakota and is affiliated with St. Alexius Medical Center. He received his Medical degree from University of Tripoli School of Medicine and has been in practice between 11-20 years. He is one of 2 doctors at St. Alexius Medical Center who is specialized in Radiation Oncology.


image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version